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The ongoing COVID-19 pandemic caused by infection with SARS-CoV-2 has created an urgent 
need for animal models to enable study of basic infection and disease mechanisms and for 
development of vaccines, therapeutics, and diagnostics. Most research on animal models for 
COVID-19 has been directed toward rodents, transgenic rodents, and non-human primates. 
The primary focus has been on the angiotensin-converting enzyme 2 (ACE2), which is a host 
cell receptor for SARS-CoV-2. Among investigated species, irrespective of ACE2 spike protein 
binding, only mild (or no) disease has occurred following infection with SARS-CoV-2, suggesting 
that ACE2 may be necessary for infection but is not sufficient to determine the outcome of 
infection. The common trait of all species investigated as COVID models is their healthy status 
prior to virus challenge. In contrast, the vast majority of severe COVID-19 cases occur in people 
with chronic comorbidities such as diabetes, obesity, and/or cardiovascular disease. Healthy 
pigs express ACE2 protein that binds the viral spike protein but they are not susceptible to 
infection with SARS-CoV-2. However, certain pig breeds, such as the Ossabaw pig, can 
reproducibly be made obese and show most aspects of the metabolic syndrome, thus 
resembling the more than 80% of the critically ill COVID-19 patients admitted to hospitals. 
We urge considering infection with porcine respiratory coronavirus of metabolic syndrome pigs, 
such as the obese Ossabaw pig, as a highly relevant animal model of severe COVID-19.
Keywords: COVID-19, animal model, metabolic syndrome, Ossabaw pig, SARS-CoV-2
INTRODUCTION
In view of the ongoing SARS-CoV-2/COVID-19 pandemic (close to 20 million cases and 
more than 700,000 deaths worldwide at the time of writing; Johns Hopkins Corona Resource 
Center, 2020), there is an urgent need to increase the understanding of basic disease mechanisms, 
expand treatment possibilities, and identify biomarkers that correlate with the onset, severity, 
and duration of the disease. This will make it possible to reduce the disease complications 
for the individual patient and for societies worldwide despite the absence of general immunity 
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toward COVID-19, be it created by efficient and comprehensive 
vaccination with yet to be  developed vaccines or by herd 
immunity caused by the pandemic itself.
Animal models that faithfully reproduce human COVID-19 
(i.e., incorporating the most important disease mechanisms, 
clinical signs, and response to treatment) are of utmost 
importance in order to achieve this. As commented by others 
(Callaway, 2020; Cleary et al., 2020; Cohen, 2020) animal species 
ranging from mice to non-human primates are actively being 
investigated in the quest for reproducible and faithful models 
of COVID-19.
THE ACE2 RECEPTOR: SPECIES 
SPECIFIC DIFFERENCES IN SARS-CoV-2 
SPIKE PROTEIN BINDING AND THE 
RELEVANCE FOR ANIMAL MODELS
A specific focus has been on the angiotensin converting enzyme 
type 2 (ACE2) that is known to be  a receptor for SARS-CoV 
(the original 2002–2003 coronavirus), and necessary for 
SARS-CoV to infect its host (Li et  al., 2003). The affinity 
between the SARS-CoV spike protein and ACE2 has been 
found to be  a major determinant for the susceptibility of the 
host to SARS-CoV infection (Wan et  al., 2020). This suggested 
ACE2 as a possible host receptor also for SARS-CoV-2. ACE2 
was indeed identified as a primary factor in determining cellular 
uptake of SARS-CoV-2 into engineered HeLa cells expressing 
ACE2 from different species (Zhou et  al., 2020). The ACE2 
from human, bat, pig, and civet but not from mouse, supported 
cellular uptake of SARS-CoV-2 (Zhou et  al., 2020). Species-
specific differences in the ability of ACE2 to bind the SARS-
CoV-2 spike protein and thus in supporting virus entry was 
also predicted in silico from the ACE2-binding site of SARS-CoV 
spike protein (Luan et al., 2020; Wan et al., 2020). In most – but 
not all – cases, a predicted or experimentally proven high 
affinity between SARS-CoV-2 and the ACE2 protein correlates 
with susceptibility of the species in question to SARS-CoV-2 
infection, although this does not always translate into disease 
(Table  1). As noted above, the predicted inability of mouse 
and rat ACE2 to bind SARS-CoV-2 (Wan et  al., 2020) was 
demonstrated experimentally (Zhou et al., 2020) and, in accord 
with this, mice have been shown not to support SARS-CoV-2 
replication and disease development (Bao et  al., 2020). Using 
engineered (transgenic) mice harboring the human ACE2 
receptor, virus propagation and development of mild disease 
has been demonstrated (Bao et al., 2020; Table 1). In addition 
to transgenic expression, human ACE2-expression in mice 
can be  achieved by CRISPR mediated humanization of the 
mouse receptor or by viral vector-mediated expression of the 
human protein (using an engineered adenovirus; Cohen, 2020). 
Other SARS-CoV-2 infection models are based on existing 
SARS-CoV models such as the Syrian hamster in which SARS-
CoV-2 has been reported to propagate and cause respiratory 
disease (Chan et  al., 2020) although only “mild SARS-CoV-2 
infection” was obtained (Sia et al., 2020). Ferrets are well-known 
models for influenza and also get infected with SARS-CoV-2; 
they express a spike protein-binding ACE2 protein, however 
only moderate disease is obtained (Kim et  al., 2020). Also, 
farmed mink have been observed to be easily infected with 
SARS-CoV-2 but again infections are generally mild (Oreshkova 
et al., 2020). Non-human primates are an obvious choice based 
on closeness to humans genetically and a study reporting 
asymptomatic lung pathology after SARS-CoV-2 infection in 
cynomolgus macaques has appeared (Rockx et  al., 2020). 
Similarly, mild symptoms in rhesus macaques with weight loss 
TABLE 1 | Susceptibility to SARS-CoV-2 infection, disease signs, and ability of 
ACE2 to bind SARS-CoV-2 spike protein as predicted (based on protein 
sequence) or shown experimentally for various species.
Species Susceptible to 
SARS-CoV-2 
infection







Pig, Sus scrofa No (2,9) No (2,9) Yes (exp) (1)
Cat, Felis catus Yes (2) Yes, especially 
young cats (2)
Yes (pred) (3)
Dog, Canis lupus 
familiaris
Yes/minor (2) No (2) Yes (pred) (3)
Mouse, Mus 
musculus













Yes (6) Mild (6) Yes (pred) (7)
Rhesus macaque, 
Macaca mulatta
Yes (8) Mild (8) Yes (pred) (7)
Masked palm civet, 
Paguma larvata










nd nd No (pred) (3)




Chicken and ducks No (2) No (2) nd
Pangolin, Manis 
pentadactyla





Yes (4) Yes (4) Yes (pred) (3)
Guinea pig, Cavia 
porcellus
nd nd No (pred) (3)
(1) Zhou et al. (2020); (2) Shi et al. (2020); (3) Luan et al. (2020); (4) Chan et al. (2020); 
(5) Bao et al. (2020); (6) Rockx et al. (2020); (7) Wan et al. (2020); (8) Munster et al. 
(2020); (9) Schlottau et al. (2020); nd: no data. The table reports on predicted spike 
protein ACE2 binding only if the interaction has not been shown experimentally.
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and signs of pneumonia but no fever were observed following 
SARS-CoV-2 inoculation (Munster et  al., 2020; Shan et  al., 
2020). Such results again stress that a SARS-CoV-2 spike protein 
binding ACE2 receptor is necessary for virus entry into cells 
but may not be  sufficient for obtaining more than mild 
COVID-19.
The pig is an interesting case, as its ACE2 protein was both 
predicted (Wan et  al., 2020) and demonstrated experimentally 
(Zhou et  al., 2020) to bind SARS-CoV-2 spike protein; however 
SARS-CoV-2 neither replicated nor caused disease in pigs after 
experimental infection (Schlottau et  al., 2020; Shi et  al., 2020).
ANIMAL MODELS OF SEVERE COVID-19
Thus, currently, no animal model of severe COVID-19 that 
reproduces the salient clinical and pathological features of the 
disease has been described. Mild symptoms are achievable in 
permissive species, but no model reproducing severe COVID-19, 
characterized by both upper and lower respiratory tract infection, 
pro-inflammatory cytokine activation, and prolonged disease 
is available, although such models obviously are of particular 
interest for investigation of intervention modalities and for 
biomarker research.
No clear correlation between ACE2 polymorphisms and 
COVID-19 susceptibility can be  established (Devaux et  al., 
2020) and generally, the receptor recognition pattern of 
coronaviruses is complex and involves one or two domains 
of the spike protein, and both protein and carbohydrate host 
receptors (Li, 2015). Receptors include dipeptidyl peptidase 4 
(receptor for MERS-CoV) and aminopeptidase N (APN), a 
receptor for the porcine respiratory coronavirus (PRCV) spike 
protein. In addition, host proteases are necessary for activating 
entry through concerted cleavage of the spike protein. Specifically, 
the spike protein of SARS-CoV-2 contains a cleavage site for 
the host protease furin (Coutard et al., 2020), which is essential 
for viral infectivity (Hoffmann et  al., 2020). Cleavage by furin 
has to be  followed by cleavage by transmembrane protease 
serine 2 (TMPRSS2) in order to fully activate the SARS-CoV-2 
spike protein, which is similar to the mechanisms used by 
MERS-CoV (Hoffmann et  al., 2020).
Observations in SARS-CoV-2-infected human subjects show 
that the disease spectrum of this infection is exceptionally 
wide, ranging from those with mild symptoms in the majority 
of cases (>80%) to severe, prolonged disease with high mortality 
and acute need for intensive care to alleviate symptoms and 
support survival (typically less than 5% of cases). A high 
proportion of the most severe cases occurs in patients with 
underlying chronic disease conditions (Deng et al., 2020; Zhou 
et  al., 2020); depending on the region, 60–80% of COVID-19 
patients requiring intensive care have at least one underlying 
co-morbidity [CDC COVID-19 Response Team (A), 2020; Tian 
et al., 2020]. In 5,700 COVID-19 patients admitted to New York 
hospitals, 88% had two or more comorbidities, the three most 
prevalent being hypertension (57%), obesity (42%), and diabetes 
(34%; Richardson et  al., 2020). Also, case fatality rates are 
elevated in patients with pre-existing comorbidities such as 
cardiovascular disease, diabetes, chronic respiratory disease, 
hypertension, and cancer (5–10% compared to overall 2.3% 
among approx. 40,000 Chinese cases; Wu and McGoogan, 2020). 
Indeed, patients with type 2 diabetes and metabolic syndrome 
have been estimated to have up to 10 times greater risk of 
death when suffering from COVID-19 (Bornstein et  al., 2020). 
Also, age, which is frequently associated with a metabolic 
syndrome-like state is an important risk factor for severe 
COVID-19. In the United  States, as registered by mid-March 
2020, of 4,226 COVID-19 cases 31% were in the above 65 years 
age group and this age group also accounted for 53% of intensive 
care unit admissions, and 80% of deaths associated with 
COVID-19 [CDC COVID-19 Response Team (B), 2020].
Cytokine storm in the lungs and inflammation are suggested 
as essential for the escalating and prolonged lung disease 
observed in severely affected COVID-19 patients, as is also 
the case for other severe human coronavirus infections like 
SARS and MERS (Mehta et  al., 2020). Intriguingly, 
immunosuppressive intervention, as often applied to treat 
pro-inflammatory cytokine over-activation may, in fact, increase 
COVID-19 severity, depending on the timing and specificity 
of the treatment (Ritchie and Singanayagam, 2020). This 
corresponds to observations on infections with animal 
coronaviruses such as PRCV (Jung et  al., 2007).
Since the majority of severe COVID-19 cases are 
characterized by having underlying chronic conditions, animal 
models incorporating such pre-existing conditions are needed 
to reproduce severe COVID-19. While other aspects of the 
infection may be  studied in any susceptible animal model, 
including genetically modified animal models, the study of 
onset, development and resolution of severe COVID-19  in 
the background of existing disease may only be  performed 
in an animal model that can reliably reproduce such 
disease states.
THE PRCV-INFECTED OBESE PIG AS 
AN ANIMAL MODEL OF SEVERE 
COVID-19
There have been at least two, independent, but unsuccessful 
attempts to infect pigs with SARS-CoV-2 (Schlottau et  al., 
2020; Shi et al., 2020). However, a range of other coronaviruses 
do infect pigs (Saif, 2004; Saif and Jung, 2020; Yang et  al., 
2020), including porcine epidemic diarrhea virus (PEDV) and 
porcine respiratory coronavirus (PRCV). As mentioned above, 
PRCV utilizes another cellular receptor than SARS-CoV-2 for 
the spike protein mediated cell entry, namely APN (Delmas 
et  al., 1993). However, as the pulmonary pathology of PRCV 
infection in pigs resembles SARS in humans PRCV infection 
of pigs was previously suggested as a model to examine SARS 
(Jung et  al., 2007). Immunosuppression by corticosteroids 
(Jung et  al., 2007; Zhang et  al., 2008) or by co-infection with 
the immunosuppressive porcine respiratory and reproductive 
syndrome virus (PRRSV; Renukaradhya et al., 2010) were both 
demonstrated to exacerbate disease after PRCV infection into 
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a SARS-like condition, with lower respiratory tract infection 
and pro-inflammatory cytokine activation. The pathogenesis 
due to PRCV infection also shows many of the same features 
as seen with SARS-CoV-2 infection (Saif and Jung, 2020), 
including a similar tissue tropism (upper and lower respiratory 
tract) and lung cellular tropism (type 1 and type 2 pneumocytes), 
and overlapping, although milder, clinical signs and lesions 
(fever, atypical pneumonia and interstitial pneumonia). Aspects 
lacking in non-complicated PRCV disease in comparison to 
COVID-19 include acute respiratory distress syndrome (ARDS), 
multiple organ failure and diffuse alveolar damage, as well 
as blood inflammatory responses and pulmonary fibrosis (Saif 
and Jung, 2020). Thus, respiratory disease due to 
non-complicated PRCV infection in pigs is a mild, self-limiting 
disease, similar to COVID-19  in most SARS-CoV-2 infected 
individuals (see above).
In line with this, we  suggest that severe COVID-19 may 
be  faithfully reproduced in PRCV-infected pigs co-affected by 
an underlying, chronic condition such as obesity associated 
metabolic syndrome. In addition to being an important 
comorbidity in the exacerbation of COVID-19 (see above), 
this syndrome has the dual characteristics of a pro-inflammatory 
state and immunosuppression (Andersen et  al., 2016); both of 
these states are speculated to promote severe COVID-19 (Ritchie 
and Singanayagam, 2020).
We would like to emphasize that in addition to closely 
mirroring human physiology, anatomy, immunology and food 
preferences, a number of pig breeds have been extensively 
documented to be  an excellent model for human diet-induced 
obesity including the spectrum of inflammation-related 
co-morbidities associated with this condition (metabolic syndrome; 
Sturek et  al., 2020). This is especially true for the Ossabaw pig 
that has been described as having the greatest capacity of any 
known, terrestrial mammal to produce and store fat (Brisbin 
and Mayer, 2001). We, and others, have documented that high 
energy and high fat diets result in the rapid occurrence of 
obesity in Ossabaw pigs (Sturek et  al., 2020). This reproducibly 
leads to a metabolic syndrome state with clinical signs such 
as hypertension, high fasting blood glucose, and dyslipidemia, 
with more advanced end-points such as pre-diabetes, non-alcoholic 
steatohepatitis (NASH), and cardiovascular disease routinely 
achieved. These conditions are accompanied by signs of a 
systemic inflammatory state with increased circulatory biomarkers 
of inflammation (Rødgaard et  al., 2013).
As described above, the pig is the natural host of a number 
of well-described coronavirus infections with various tropisms 
and virulence. None of these viruses are human pathogens. 
PRCV has been demonstrated, both by intranasal and 
intratracheal instillation, to lead to respiratory disease in pigs, 
although with low morbidity and mortality (Saif, 2004). As 
also described above, the outcome of the infection was worsened 
by immunosuppression with dexamethasone (Jung et  al., 2007; 
Zhang et  al., 2008). We  hypothesize that disease severity will 
increase in obese Ossabaw pigs infected with PRCV compared 
to pigs of normal weight, and hence will constitute a useful 
model for severe COVID-19 in humans at risk due to metabolic 
syndrome associated comorbidities, including aged individuals. 
With the added benefit of being a well-described pig-specific 
virus (with no rigorous biosafety demands), we  suggest that 
the obese pig affected by the metabolic syndrome will constitute 
a highly human-translatable animal model having the potential 
to significantly facilitate and accelerate SARS-CoV-2/COVID-19 
research. Both basic disease mechanisms and the efficacy and 
safety of therapeutic drug candidates for treatment of COVID-19 
patients from high risk groups can potentially be  studied in 
this model as can biomarkers for severe COVID-19; such 
markers are of high importance to identify individuals facing 
severe disease progression to allow early treatment decisions.
DISCUSSION
In summary, there is a compelling need for animal models 
for COVID-19 that accurately reproduce severe COVID-19, 
as these human cases are currently non-treatable and have 
resulted in very severe societal measures having detrimental 
economic and political consequences worldwide. While a range 
of animal species are indeed permissive for SARS-CoV-2 
infection, only mild or no disease is obtained upon infection. 
We suggest that a relevant and valid model of severe COVID-19 
should preferentially incorporate the most common comorbidities 
of severe COVID-19, such as metabolic syndrome, type 2 
diabetes, and hypertension, also associated with age. We propose 
that the persistent inflammation that is part of the metabolic 
syndrome increases the risk of a cytokine storm during 
coronavirus infection linking an aberrant metabolic state to 
severe COVID-19.
Non-human primates may be  highly relevant as models 
for SARS-CoV-2 infection, however developing primate 
comorbidity models will be  expensive and time-consuming. 
Pig models are highly relevant to human medicine because 
they closely mimic human anatomy, physiology, and 
immunology. Furthermore, they develop robust metabolic 
syndrome and cardiorespiratory disease upon diet-induced 
obesity. Intranasal inoculation of PRCV in pigs with robust 
metabolic syndrome such as obese Ossabaw miniature pigs, 
may increase the severity of disease, similar to patients with 
metabolic syndrome having severe COVID-19. This type of 
animal model could accelerate coronavirus research on basic 
disease mechanisms, biomarkers, and therapeutics for 
COVID-19 patients in high-risk groups.
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